1. Allergen-loaded strontium-doped hydroxyapatite spheres improve allergen-specific immunotherapy in mice.
- Author
-
Garbani, M., Xia, W., Rhyner, C., Prati, M., Scheynius, A., Malissen, B., Engqvist, H., Maurer, M., Crameri, R., and Terhorst, D.
- Subjects
- *
ALLERGY diagnosis , *DENDRITIC cells , *IMMUNOTHERAPY , *MICROPARTICULATED proteins , *ANIMAL models in research - Abstract
Background Immunomodulatory interventions play a key role in the treatment of infections and cancer as well as allergic diseases. Adjuvants such as micro- and nanoparticles are often added to immunomodulatory therapies to enhance the triggered immune response. Here, we report the immunological assessment of novel and economically manufactured microparticle adjuvants, namely strontium-doped hydroxyapatite porous spheres ( SHAS), which we suggest for the use as adjuvant and carrier in allergen-specific immunotherapy ( ASIT). Methods and results Scanning electron microscopy revealed that the synthesis procedure developed for the production of SHAS results in a highly homogeneous population of spheres. Strontium-doped hydroxyapatite porous spheres bound and released proteins such as ovalbumin ( OVA) or the major cat allergen Fel d 1. SHAS- OVA were taken up by human monocyte-derived dendritic cells (md DCs) and murine DCs and did not have any necrotic or apoptotic effects even at high densities. In a murine model of ASIT for allergic asthmatic inflammation, we found that OVA released from subcutaneously injected SHAS- OVA led to a sustained stimulation of both CD4+ and CD8+ T cells. Allergen-specific immunotherapy with SHAS- OVA as compared to soluble OVA resulted in similar humoral responses but in a higher efficacy as assessed by symptom scoring. Conclusion We conclude that SHAS may constitute a suitable carrier and adjuvant for ASIT with great potential due to its unique protein-binding properties. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF